{"organizations": [], "uuid": "23a72a2bdbb3276073ac695f2f6c99e4fa21b218", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180214.html", "section_title": "Archive News &amp; Video for Wednesday, 14 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-novartis-forms-alliance-for-treati/brief-novartis-forms-alliance-for-treating-infectious-diarrheal-disease-idUSFWN1Q403U", "country": "US", "domain_rank": 408, "title": "BRIEF-Novartis forms alliance for treating infectious diarrheal disease", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-02-14T14:21:00.000+02:00", "replies_count": 0, "uuid": "23a72a2bdbb3276073ac695f2f6c99e4fa21b218"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-novartis-forms-alliance-for-treati/brief-novartis-forms-alliance-for-treating-infectious-diarrheal-disease-idUSFWN1Q403U", "ord_in_thread": 0, "title": "BRIEF-Novartis forms alliance for treating infectious diarrheal disease", "locations": [], "entities": {"persons": [{"name": "michael shields", "sentiment": "none"}, {"name": "melinda gates", "sentiment": "none"}], "locations": [{"name": "us", "sentiment": "none"}], "organizations": [{"name": "novartis ag", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "novartis", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 14 (Reuters) - Novartis AG:\n* NOVARTIS FORMS ALLIANCE TO DEVELOP MEDICINES FOR TREATING INFECTIOUS DIARRHEAL DISEASE\n* GETS FUNDING FROM BILL & MELINDA GATES FOUNDATION FOR FURTHER DEVELOPMENT OF DRUG CANDIDATE KDU731 FOR CRYPTOSPORIDIOSISâ€‹ Source text for Eikon: Further company coverage: (Reporting By Michael Shields)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-14T14:21:00.000+02:00", "crawled": "2018-02-15T20:20:12.023+02:00", "highlightTitle": ""}